|LETTER TO EDITOR
|Year : 2022 | Volume
| Issue : 1 | Page : 158-159
Indian real-world data on melanoma
Department of Surgical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
|Date of Submission||20-Jan-2022|
|Date of Decision||25-Jan-2022|
|Date of Acceptance||25-Jan-2022|
|Date of Web Publication||24-Feb-2022|
H N Arun
Department of Surgical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Arun H N. Indian real-world data on melanoma. Cancer Res Stat Treat 2022;5:158-9
I read with great interest the observational study from the prestigious All India Institute of Medical Sciences in Delhi, India, titled “Clinical profile and outcomes of malignant melanoma in patients from an Indian institute: A retrospective analysis” and the accompanying editorial., First, the results truly reflect the health-care referral system in India as most cases (89%) of melanoma being managed at tertiary care centers present in the metastatic stage. My recommendation is that a wide variety of types of melanomas should be grouped according to the anatomical locations to obtain a meaningful comparison of the treatment outcomes, for example, mucosal melanoma, extremity melanoma (upper and lower), truncal, head and neck, and choroidal. The biological behavior of melanoma in each of these situations would vary, and apart from the histopathological type, the pattern of the locoregional neurovasculature as well as the lymphatics would dictate the tumor spread. For example, choroidal melanoma cells have liberal access to the retinal vasculature and will therefore rapidly spread systemically. We have seen two cases of melanosis peritonei upon opening the abdomen, which had been earlier diagnosed as ovarian carcinoma in a patient who had undergone prior enucleation of the eye. Retrospective questioning revealed the clue of the prior enucleation as the source of the current intra-abdominal malignancy. I request the authors to comment on this and to provide the treatment outcomes in their cohort of patients based on the anatomical location.
Finally, given the notable response rates from PD-L1 inhibitors in melanoma, it is unfortunate that they are unaffordable for the majority of Indian patients., We hope that over time, the prices will come down, which may make these medicines more affordable for our patients.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Shishak S, Mittal A, Aswar H, Pandey R, Kalra K, Gupta A, et al.
Clinical profile and outcomes of malignant melanoma in patients from an Indian institute: A retrospective analysis. Cancer Res Stat Treat 2021;4:621-7. [Full text]
Raja A, Krishnan CK. Melanoma: Gaps in knowledge and treatment. Cancer Res Stat Treat 2021;4:728-30. [Full text]
Radhakrishnan V. Drug pricing: A major barrier to access to cancer care in India. Cancer Res Stat Treat 2021;4:195-7. [Full text]
Patel AA. One foot in the door: Financial toxicity in patients with cancer receiving active chemotherapy. Cancer Res Stat Treat 2021;4:170-1. [Full text]
Prinja S, Gupta N. Value-based pricing for cancer drugs in India. Cancer Res Stat Treat 2021;4:559-60. [Full text]